Theme 5. Clinical trials: Cognitive and functional endpoints

P2 - Objectively measured physical activity and cognitive function
Hiroyuki Umegaki1, Taeho Mahito2, Kazuki Uemura3, Hiroyuki Shimada4, Xian Wu Cheng5
1MD, PhD Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan; 2PhD Institute of Innovation for Future Society, Nagoya University, Aichi, Japan; 3Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan; 4Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan; 5PhDb, Masafumi Kuzuya, MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan

P3 - D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer’s disease: Implications for dentate gyrus activity and neurogenesis
Pascal J. D. Goetghebeur1, Keith A. Wesnes2, Steven D. Targum3
1Bracket LLC, Reading, UK; 2Wesnes Cognition Ltd, Streteley on Thames, UK; 3Bracket LLC, Boston, US

P8 - A Multicenter, Open-label, 24-week Follow-up Study for Efficacy on Cognitive Function of Donepezil inBinswanger-Type Subcortical Vascular Dementia
Jay Cheol Kwon, M.D.1, Eung Gyu Kim, M.D.1, Jae Woo Kim, M.D.1, Oh Daewon Kwon, M.D.1, Hong Goo Yoo, M.D.1, Nam-Gon Kim, M.D.1, Nach Cheon Choi, M.D.1, Seon young Ahn, M.A., Byung Hwa Lee, M.D.1, Myong Jin Kang, M.D.1, Dae Seob Choi, M.D.1, The BKVD Study Group
Department of Neurology, Changuwon Fasino Hospital, 1Inje University Pusan Paik Hospital, 2Dong-A University Medical Center, 3Daegu Catholic University Medical Center, 4Kosin University Gospel Hospital, 5Gimhae Jungang Hospital, 6Gyeongsam National University Hospital, 7Department of Radiology, 8Dong-A University Medical Center, 9Gyeongsang National University Hospital

P9 - The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain MRI and Cognitive Decline in Seventh Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Study
Jay Cheol Kwon, M.D., PhD., Kyungsoo Lee, MD, Yohan Jung, MD, PhD., Sungiae Cho, MD, PhD. And Nach-cheon Choi, MD, PhD.
Changuwon Fasino Hospital, Changuwon, Korea, The Republic of; Samsung Changuwon Hospital, Changuwon, Korea, The Republic of; Gyeongsam National University Hospital, Chinh, Korea, The Republic of

P19 - Lanabecestat: Central monitoring of rater performance and error characteristics of efficacy assessments in theAMARANTH study
Atette M. Wessels1, Lisle R. Kingery2, Edward I. Bartolic3, Laura E. Nichell4, Jamie A. Mullen4, John R. Sims1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Cogstate, New Haven, USA, 3AstraZeneca Pharmaceuticals, Cambridge, MA, USA

P25 - Effects of sex, educational background, and CKD grading on cognitive and functional decline in Japanese ADNI study
Atsushi Iwata, MD1, Ryoko Ihara, MD2, Kazushi Suzuki, MD2, Takeshi Iwatsubo, MD2, and the Japanese ADNI1
Department of Neurology, The University of Tokyo Hospital, Tokyo, Japan; 2Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital Tokyo, Japan

P26 - A German version of the “Five Word Test” – Discriminating patients with mild cognitive impairment/mild Alzheimer’s disease, healthy controls and patients with depression
Hausner L, MD, Dinu-Biringer R, PhD, Frölich L, MD, PhD
Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany

P27 - Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment
Shim YongSoo, Jung San
Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea, Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 327 Sosa-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 16467, Republic of Korea, Tel: B2-32-340-7094 - Fax: B2-32-340-2669 - E-mail: ysshim@catholic.ac.kr

P53 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Barbone, BA1, Todd M. Solomon, PhD1, H. Todd Feaster, PsyD1, Macarena Garcia-Valdecasas Colell, MSc2, & David S. Miller, MD, MA1
1Bracket, Wayne, PA, USA; 2Boston University School of Medicine, Boston, MA, USA

P67 - The presence of identical scoring on the MMSE and ADCS-ADL in Alzheimer’s disease clinical trials using enhanced eCOA devices
Todd M. Solomon, Ph.D.1, 2, Jordan Mark Barbone, B.A., Sarah M. Karas, Psy.D., Danielle T. DiGregorio, Psy.D., Michael R. Maddock, MA1, David M. Miller, MD1, H. Todd Feaster, PsyD1
1Bracket, Wayne, PA, USA; 2Boston University School of Medicine, Boston, MA, USA
P69 - Neuroplasticity-based visual alertness training and improvements in declining executive functions in healthy older adults

Thomas Van Vleet, PhD1, Joseph DeGutis, PhD2,3, Michelle Voss, PhD4
1Research and Development, Pasit Science, San Francisco, CA, USA, 2School of Medicine, Harvard University, Boston, MA, USA, 3Boston VA, Boston, MA, USA, 4Psychology Department, University of Iowa, Iowa City, IA, USA

P71 - The treatment response of Goal Attainment Scaling in relation to goal number in a clinical trial of Alzheimer’s Disease Patients

Kenneth Rockwood, MD3, Lisa McGarrigle, PhD3
1Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, 2DGI Clinical Inc, Halifax, NS, Canada

P74 - Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study

Anzalee Khan PhD2,3, Danny Ushen BA1, Alexandra Atkin PhD1, Danela Balantin BA1, Adam Vaughan PhD1, Heather Dickerson PhD1, Brenda L. Plassman PhD3, Kathleen A. Welsh-Bohmer PhD1, Rich Keeve PhD1,3
1NeuroCog Trials, Durham, NC, USA, 2Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, 3Duke University, Durham, NC, USA

P77 - Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials

Selam Negash1, Christopher Weber, Christopher Randolph1,2
1MedAvante-ProPhase, 2Loyola University Medical Center

P83 - Determinants of care refusal: from patients suffering from dementia to their caregivers characteristics’

Gaëstel, Y, Phd, CERDA S, MD
Memory Center, Bagotelle Hospital, Talence, France

P140 - Item bias in the measurement of functional impairment: a cross-cultural comparability study in eight international cognitive aging studies

Sietse A. M. Sijtses, PhD1,2, Mark A. Dubbelman, MSC1, Meriite Verrijp, MSC1, Gonzalo Sánchez Benavides, PhD1, David Facal, PhD1, Bruno Dubois, MD, PhD3, Wiesje M. van der Flier, PhD3,4, Hanna Jokinen, PhD3, Cristina Lojo-Seoane4, José Luis Molinuevo, MD, PhD1,3, Arturo X. Pereiro Rozas, PhD1, Craig Ritchie, MD, PhD1, Magdalina Tsaloli, MD, PhDB,5, Ya-Huei Wu, PhDB,5, Stelios Zygouris, MSc6,7, Stephane Epelbaum, MD, PhD1, Philip Schelten, MD, PhD1
1Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, 2Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 3BarcelonaBeta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, 4Hôpital Pitié-Salpêtrière, IM2A, PARIS, France, 5Department of Developmental Psychology, University of Santiago de Compostela, Spain, 6Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland, 7Department of Psychiatry, Charité University Medicine, Berlin, Germany, 81st Department of Neurology, Aristotle University of Thessaloniki, Greece, 9Gree Association of Alzheimer’s Disease and Related Disorders, Greece, 10Braco Hospital, Paris, France II Neuroimaging Assessment Research, University of Heidelberg, Germany


Susan Abushakra MD1, Bruno Vellas MD2, Serge Gauthier MD3, Anton Porsteinsson MD1, Cari Sadowsky MD1, Aidan Power MD1, Larry Shen PhD1, Lu Wang MS5, Tim Lin MS5, John Hey PhD1, Martin Tolar MD PhD1
1*Alzheon, Inc, Framingham, MA, USA, 2University of Toulouse, Toulouse, France, 3McGill University, Montreal, Canada, 4University of Rochester, Rochester, New York, 5Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida, 6Pharmapace, Inc., San Diego, CA

P142 - Exploring Genetic Associations of Alzheimer’s Disease Loci with Mild Impairment Neuropsychometric Endophenotypes. Impact on cognitive and functional endpoints

Ana Espinosa, PhD1,2, Begona Hernández-Olazaragre, PhD1, Sonia Moreno-Grau, MSC1, Luca Kleiniedich, MSC1,2,3, Stefanie Heilmann, PhD1,4, Isabel Hernández, MD, PhD2, Steffen Wolfsgruber, Dipl.-Psych.2,3, Holger Wagner, MSc1,2, Maitée Rosende-Roca, MD1, Ana Mauleón, MD1, Liliana Vargas, MD1, Asuncion Lafuente, MD1, Octavio Rodríguez-Gómez, MD, MD1, Carla Abelndeur, MD1, Silvia Gil, MD, PhD1, Marta Marquié, MD1, PhD1, Miguel A. Santos-Santos, MD2, Angela Sanabria, PhD1, Gemma Ortega, PhD1, Gemma Monté, PhD1, Alba Pérez, MSc1, Marta Ibarria, MSc1, Susana Ruiz, MSc1, Johannes Kornhuber, MD, PhD1, Oliver Peters, MD1, Lutz Frölich, MD, PhD1, Michael Hüll, MD1, Jens Wittfjang, MD1, Martin Scherer, MD1, Tobias Luck, Dipl.-Psych.1, Steffi Riedel-Heller, MD3, Laura Montreuil, MSc1, Pilar Cariabate, PhD1, Maria Moreno, MSc1, Silvia Preciacher, MSc1, Nuria Aguillera, MSc1, Iziar de Rojas, MSc1, Adela Orellana, PhD1, Montserrat Alegría, PhD1, Sergio Valero, PhD1, Markus K Nöthen, MD1,2, Michael Wagner, PhD1,3, Fourt Jessen, PhD1,3, Wolfgang Maier, MD1,3, Luis Tarraga, MSc1, Mercè Boada, MD1, PhD1, Alfredo Ramirez, MD1, PhD4,5 and Agustin Ruiz, MD, PhD1
1Research Center and Memory Clinic, Fundació ACE. Institut Català de Neurociències Aplicades, IUC-Barcelona, Spain, 2German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, 3Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, 4Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, 5University of Human Genetics, University of Bonn, Bonn, Germany, 6Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany, 7Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, 8Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Erlangen, Germany, 9Department of Psychiatry, Charité University Medicine, Berlin, Germany, 10Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, 11Center for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Freiburg, Germany, 12Department of Psychiatry and Psychotherapy, University of Cottbus-Cotteningen, Germany, 13Departments of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 14Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany
PI43 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort study (LCS)

Michael T. Ropacki, PhD,1 John Harrison, PhD,2,3 Joel Kramer, PsyD,4 Christopher Randolph, PhD,4 Jeffrey Kaye, MD,5 Bruce Albala, PhD,5 Karen Ritchie, PhD6

1Strategic Global Research & Development, Half Moon Bay, USA, 2Meis Cognition Ltd, UK, 3Alzheimer Center VUmc, Amsterdam, Netherlands, 4Department of Neurology, Memory, and Aging Center, University of California at San Francisco, San Francisco, USA, 5Department of Neurology, Loyola University Medical Center, Maywood, USA, 6Neurology and Biomedical Engineering, Oregon Health and Science University, Portland, USA, 7Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatrie, Montpellier, France, 8Faculty of Medicine, University of Montpellier, Montpellier, France, 9Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK

PI44 - Two distinct modelling approaches of cognitive decline and time to diagnosis of MCI/dementia to inform study design and to improve risk prediction in preclinical Alzheimer’s Disease

Angelita Caputo, PhD,1 Ana Graf, MD,1 Cristina Lopez Lopez, PhD, MD,1 Valery Risson, PhD,2 Giulia Lestini, PhD,2 Neva Coello, PhD,2 Amy Racine, PhD,2 Ines Paule, PhD,2 Luyuan Qi, PhD,3 Helene Karcher, PhD3

1Novartis Pharma AG, Basel, Switzerland, 2Analytica Laser, a Certara company, Paris, France, 3Analytica Laser, a Certara company, London, UK

PI45 - Ability of an online object pattern separation test to detect potential disruptions to hippocampal neurogenesis associated with ageing, gender, lifestyle and disease in a large cohort of older adults

Keith A. Wesnes PhD,1 Helen Brooker BSc,2,3 Clive Ballard MD, PhD,1 Dag Aarsland MD, PhD,1 Zunera Khan MSc,3 Maria Megalogeni MSc,3 Anne Corbett PhD

1University of Exeter Medical School, University of Exeter, Exeter, UK, 2Wesnes Cognition Ltd, Sreatley on Thames, UK, 3King’s College London, London, UK

PI46 - Comparison of sleep measurements from actigraphy to self-reported sleep diaries

Kirsti Kinnunen PhD1, Richard Joules, PhD1, Janet Munro, MPhil1, Iain Simpson PhD1, Robin Wolz, PhD2, Yves Dauvilliers, MD PhD3

1IXICO Plc, London, UK, 2Imperial College London, London, UK, 3Sleep Unit, Department Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM 1061, France

PI47 - Using DCTclock’s clinically-interpretable artificial intelligence for differentiating cognitively healthy subjects from amnestic Mild Cognitive Impairment and probable Alzheimer’s Disease

William Souillard-Mandar1, Braydon Schaible1, Randall Davis PhD2, Rhoda Au PhD3, Dana Penney PhD4

1Digital Cognition Technologies, Inc., Waltham, MA, USA, 2MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA, 3Boston University Schools of Medicine and Public Health, Boston, MA, USA, 4Lahey Hospital and Medical Center, Burlington, MA, USA

PI48 - Advancing Clinical and Biomarker Research in AD: The LEAD Study

Liana G. Apostolova, MD, Paul Aisen, MD, Ani Eloyan, PhD, Anne Fagan, PhD, Tatiana Foroud, PhD, Constantine Gatsonis, PhD, Clifford Jack, MD, Joel Kramer, PsyD, Robert Koepppe, PhD, Andrew Saykin, PsyD, Arthur Toga, PhD, Prashanthi Vemuri, PhD, Gregory Day, MD, MSc, Neill Graff-Radford, MD, Lawrence Honig, MD, David Jones, MD, Sterling Johnson, PhD, Joseph Masdeau, MD, Mario Mendez, MD, Chiadi Onyike, MD, Emily Rogalski, PhD, Steve Salloway, MD, David Waltz, MD, Thomas Wingo, MD, Maria Cantillo, PhD, Brad Dickerson, MD, Gil Rabinovici, MD

PI49 - Measuring Pre-Clinical Cognitive Decline over Time: Separating and Combining Alzheimer’s Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores

Suzanne Hendrix PhD,1 Noel Ellison, MS2, Jessica B. Langbaum, PhD2, Kewei Chen, PhD3 and David A. Bennett, MD4

1Pentara Corporation, Milcreet, UT, USA, 2Arizona Alzheimer’s Consortium, Phoenix, AZ, USA, 3University of Arizona, Tucson, AZ, USA, 4Rush University, Chicago, IL, USA